Journal
JOURNAL OF CANCER
Volume 11, Issue 6, Pages 1299-1307Publisher
IVYSPRING INT PUBL
DOI: 10.7150/jca.34423
Keywords
p62; VK3; ROS; Drug resistance; Nrf2; Keap1
Categories
Funding
- National Natural Science Foundation of China [81672948, 81202552]
- Jilin Provincial Research Foundation for International Science and Technology Cooperation Projects, China [20160414005GH]
- Jilin University Bethune Plan B Projects [2015222]
Ask authors/readers for more resources
Imbalance of redox homeostasis may be responsible for the resistance of cancer to chemotherapy. Currently, increasing studies demonstrated that vitamin K3 (VK3), which promoted the production of ROS, had potential to be developed as an anti-tumor agent. We found SKOV3/DDP cells with high levels of p62 were insensitive to VK3 compared with SKOV3 cells. Furthermore, Nrf2 downstream antioxidant genes such as HO-1(heme oxygenase 1) and NQO1 (NAD (P) H: quinone oxidoreductase 1) were upregulated in SKOV3/DDP cells with VK3 treatment, which indicated VK3 activated Nrf2 signaling in SKOV3/DDP cells. Moreover, co-localization of p62 and Keap1 was also observed. Suppression of p62 expression increased the apoptosis induced by VK3, and the expression of Nrf2, HO-1 and NQO1 were all downregulated in SKOV3/DDP cells. Our results suggested that overexpressed p62 may protect cells from oxidative damage caused by VK3 through activating Keap1/Nrf2 signaling in ovarian cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available